Amarin Corp Plc (AMRN)

[dukesking]

Kiwi, that’s obviously a strategy that Hikma might determine is their best option and pursue it. It doesn’t make financial sense to me, in an unripe market with no ability to advertise cardiovascular risk reduction or grow through marketing, and competition from other generics 6 months down the road. It also doesn’t make sense for AMRN to continuing advertising and promotion after that happens. I agree that if and when Hikma launches that AMRN should cease all promotion and launch a generic version of their own and preserve capital and focus on EU launch. I‘m hoping that Hikma and others agree there is a win win strategy they could pursue with AMRN that is mutually beneficial that doesn’t require vacating the courts ruling. Hope that helps clear up what I was referring to.